These results revealed a new mechanism that controls the CUL3 E3 ligase by its adaptor protein KEAP1 and recognizes that inhibiting the SUMOylation of KEAP1 may be a promising strategy for tumor therapy. Here, KEAP1 is linked to neoplasm.